Market capitalization | $387.49m |
Enterprise Value | $554.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 75.19 |
EV/Sales (TTM) EV/Sales | 1.23 |
P/S ratio (TTM) P/S ratio | 0.86 |
P/B ratio (TTM) P/B ratio | 0.95 |
Revenue growth (TTM) Revenue growth | -48.85% |
Revenue (TTM) Revenue | $451.29m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a ZimVie forecast:
3 Analysts have issued a ZimVie forecast:
Sep '24 |
+/-
%
|
||
Revenue | 451 451 |
49%
49%
|
|
Gross Profit | 261 261 |
49%
49%
|
|
EBITDA | 43 43 |
44%
44%
|
EBIT (Operating Income) EBIT | -9.10 -9.10 |
81%
81%
|
Net Profit | -349 -349 |
293%
293%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Westminster, CO.
Head office | United States |
CEO | Vafa Jamali |
Employees | 2,600 |
Founded | 2021 |
Website | www.zimvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.